Thus, if drugs or procedures to increase mTOR activity in a T cell–specific manner are developed in the future, such novel treatments and PD-1 blockade may be used simultaneously to further enhance therapeutic efficacy in patients with cancer. The gene discussed is MTOR; the disease is cancer.